Phathom Pharmaceuticals grabs $90 mln
Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.
15 May 2019•5 mins read
